{"created":"2023-05-15T15:12:17.394321+00:00","id":33,"links":{},"metadata":{"_buckets":{"deposit":"8ba60ae8-cc15-4f82-a2c1-ed506bb4206b"},"_deposit":{"created_by":12,"id":"33","owners":[12],"pid":{"revision_id":0,"type":"depid","value":"33"},"status":"published"},"_oai":{"id":"oai:ompu.repo.nii.ac.jp:00000033","sets":["1:11"]},"author_link":["39"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2008","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"118","bibliographicPageStart":"111","bibliographic_titles":[{"bibliographic_title":"大阪薬科大学紀要"},{"bibliographic_title":"Bulletin of Osaka University of Pharmaceutical Sciences","bibliographic_titleLang":"en"}]}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"大阪薬科大学"}]},"item_10002_relation_12":{"attribute_name":"論文ID（NAID）","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"40015898067","subitem_relation_type_select":"NAID"}}]},"item_10002_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA12214244","subitem_source_identifier_type":"NCID"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"金, 啓二"}],"nameIdentifiers":[{"nameIdentifier":"39","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2015-02-02"}],"displaytype":"detail","filename":"7_kim_kiyo08p.pdf","filesize":[{"value":"1.7 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"7_kim_kiyo08p","url":"https://ompu.repo.nii.ac.jp/record/33/files/7_kim_kiyo08p.pdf"},"version_id":"bb369dd4-3b1b-43d8-ad1e-be077f94e8cb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"2',5'-oligoadenylate synthetase","subitem_subject_scheme":"Other"},{"subitem_subject":"chronic hepatitis C","subitem_subject_scheme":"Other"},{"subitem_subject":"PEG-IFN","subitem_subject_scheme":"Other"},{"subitem_subject":"ribavirin","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"C型慢性肝炎に対するペグインターフェロンとリバビリン併用療法:抗ウイルス効果判定の指標としての2-5AS活性測定の意義","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"C型慢性肝炎に対するペグインターフェロンとリバビリン併用療法:抗ウイルス効果判定の指標としての2-5AS活性測定の意義"},{"subitem_title":"2',5'-oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"12","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-02-02"},"publish_date":"2015-02-02","publish_status":"0","recid":"33","relation_version_is_last":true,"title":["C型慢性肝炎に対するペグインターフェロンとリバビリン併用療法:抗ウイルス効果判定の指標としての2-5AS活性測定の意義"],"weko_creator_id":"12","weko_shared_id":-1},"updated":"2023-05-15T19:30:31.506838+00:00"}